Zebra Nusantara Will Cooperate With A South Korean Company To Develop COVID-19 PCR Reagan
JAKARTA - PT Zebra Nusantara Tbk (ZBRA) continues to expand its business. Not satisfied with this year's net sales which grew by 30.000 percent, the company under the command of Rudy Tanoesoedibjo will cooperate with companies from South Korea in the health sector.
The situation of the COVID-19 pandemic in the world and especially in Indonesia, which is still happening today, has forced companies with the issuer code of ZBRA to take part in the recovery of this pandemic.
"ZBRA projects to collaborate with large South Korean companies to develop COVID-19 PCR reagents locally with South Korean advanced technology. This is of course very important for the pandemic situation in Indonesia, especially for the COVID-19 checking process in the community. Besides that, it is also an important step in helping the government get Indonesia out of the COVID-19 pandemic," said Director of ZBRA Gary Tanoesoedibjo, in a press release, Wednesday, October 27.
Gary explained that currently, his company is still in the stage of exploring cooperation with the South Korean company. This ginseng-based company focuses its business in the health sector and also in the provision of modern health services.
The company has been active in research and development with renewable technology to provide qualified health services.
"Health services and various products developed by the South Korean company have been officially certified by government agencies in South Korea. So they can guarantee the services and products they market," said Gary.
SEE ALSO:
Gary explained that the collaboration will be in the form of technology transfer related to the "National Genetic Molecular Diagnostic" and "Molecular Diagnostic Kit" laboratories that are needed in this pandemic situation.
"With this business collaboration, it is hoped that ZBRA can improve the quality of local products because it has succeeded in providing local products designed with tested and certified technology from South Korea, especially the development of the COVID-19 PCR reagent which is currently the highlight in the last 2 years," he added.